Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
09 November 2022 - 8:05AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced that
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of
Atea Pharmaceuticals, will participate in and present a business
update at the Jefferies London Healthcare Conference on Tuesday,
November 15 at 5:00 p.m. GMT / 12:00 p.m. ET. The event can be
accessed here.
A live webcast and recording of the presentation will also be
available under "Events and Presentations" in the Investor
Relations section of the Atea Pharmaceuticals website
at https://ir.ateapharma.com/. An archived webcast will be
available on Atea Pharmaceuticals’ website approximately two hours
after the event and will remain available for at least 90 days
following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with severe diseases.
Leveraging the Company’s deep understanding of antiviral drug
development, nucleos(t)ide chemistry, biology, biochemistry and
virology, Atea has built a proprietary nucleos(t)ide prodrug
platform to develop novel product candidates to treat single
stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent
cause of severe viral diseases. Atea plans to continue to build its
pipeline of antiviral product candidates by augmenting its
nucleos(t)ide platform with other classes of antivirals that may be
used in combination with its nucleos(t)ide product candidates.
Currently, Atea is focused on the development of orally-available
antiviral agents for difficult-to-treat, severe viral infections,
including severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus
(HCV), dengue virus and respiratory syncytial virus (RSV). For more
information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our expectations surrounding the potential of our product
candidates, including bemnifosbuvir combination product candidates,
and expectations regarding our pipeline, including trial design and
development timelines. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
uncertainty around and costs associated with the clinical
development of bemnifosbuvir as a potential treatment for COVID-19
and HCV and the clinical development of AT-752 for the potential
treatment or prevention of dengue. These and other important
factors discussed under the caption “Risk Factors” in our Annual
Report on Form 10-K for the year ended December 31, 2021 and our
other filings with the SEC could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Apr 2023 to Apr 2024